arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Veradermics, Incorporated

MANE Health Care Biotechnology: Pharmaceutical Preparations
$138.78
▲ +1.6% Today
as of Oct 23, 16:50 ET
Last 30 days +36.46% Sep 14 → Oct 23
$98.73 $109.49 $120.24 $130.99 $141.75 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$139.44
High
$139.86
Low
$134.49
Volume
$423,083
Avg Vol
$663,518
Mkt Cap
$4.8B
P/E (TTM)
—
Beta
—
52w High
$141.75
52w Low
$32.00
Div Yield
—
Shares Out
$42M

Recent Press Releases & News last 60 days · 12 items

Oct 22 · 12:07 MT Newswires
B. Riley Raises Price Target on Veradermics to $204 From $170, Keeps Buy Rating
Oct 19 · 17:18 Clinical Trials Arena
Veradermics’ stock up on male hair loss trial success
Oct 19 · 17:07 TIKR
Veradermics Soars 10% as Phase 3 Data Show Oral Hair-Loss Pill Could “Transform” Treatment
▸ Show all 12 press releases & news Free account →

MANE earnings at a glance

The options market is pricing a move of about ±21.3% after the report, a range of roughly $109.17 to $168.39 from today's $138.78. Over its last 1 reports the stock rose the next day 0 times and fell 1, moving ±3.9% on average; after the most recent report on May 12, 2026 it moved -3.9%. That means options currently expect more movement than MANE has typically delivered. MANE beat the consensus EPS estimate in 0 of its last 1 reported quarters. Implied volatility is currently 181%. The share price of $138.78 sits near its 52-week high.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$32
$142
97% of range
Avg surprise (last 1)
-135.7%
Avg reaction (last 1)
-3.9%
0% positive
Latest IV / EM
181%
EM ±21.3% · $125 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-24.19$-18.28$-12.38$-6.47$-0.56 Actual $-19.79Actual $-24.19Actual $-1.32Est $-0.56Actual $-0.58 MarJunMar/2026Jun
Revenue vs Net Income Revenue Net income
$-27M$-24M$-20M$-17M$-13M Mar 25Jun 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.58 — — — — financials
Tue May 12, 2026Mar/2026 $-1.32 $-0.56 -135.7% — -3.9% earnings
Mon Jun 30, 2025Jun 2025 $-24.19 — — — — financials
Mon Mar 31, 2025Mar 2025 $-19.79 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Jun 2025Mar 2025
Revenue—————
Cost of revenue—————
Gross profit—————
Operating income$-30M$-30M—$-16M$-13M
Net income$-24M$-27M—$-16M$-12M
EPS (diluted)$-0.58$-1.32—$-24.19$-19.79

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Jun 2025Mar 2025
Cash & equivalents$319M$168M$22M——
Inventory—————
Total current assets$825M$397M$152M——
Total assets$826M$397M$153M——
Long-term debt—————
Total liabilities$12M$7M$9M——
Total equity$814M$391M$-121M$-76M$-61M

Implied volatility — last 90 days

83%108%132%156%180% Jul 15 — IV 95% · EM ±24.1%Jul 16 — IV 95% · EM ±23.9%Jul 17 — IV 104% · EM ±25.6%Jul 20 — IV 104% · EM ±24.6%Jul 21 — IV 104% · EM ±24.3%Jul 22 — IV 103% · EM ±23.5%Jul 23 — IV 96% · EM ±21.6%Jul 24 — IV 101% · EM ±22.4%Jul 27 — IV 103% · EM ±21.5%Jul 28 — IV 103% · EM ±21.0%Jul 29 — IV 104% · EM ±20.9%Jul 30 — IV 99% · EM ±19.4%Jul 31 — IV 106% · EM ±20.2%Aug 03 — IV 101% · EM ±17.8%Aug 04 — IV 100% · EM ±17.2%Aug 05 — IV 97% · EM ±16.1%Aug 06 — IV 99% · EM ±16.0%Aug 07 — IV 96% · EM ±14.9%Aug 10 — IV 102% · EM ±14.1%Aug 11 — IV 84% · EM ±11.2%Aug 12 — IV 88% · EM ±11.0%Aug 13 — IV 88% · EM ±10.4%Aug 14 — IV 94% · EM ±10.4%Aug 17 — IV 101% · EM ±8.4%Aug 18 — IV 84% · EM ±6.1%Aug 19 — IV 98% · EM ±5.8%Aug 20 — IV 124% · EM ±5.2%Aug 24 — IV 111% · EM ±23.1%Aug 25 — IV 110% · EM ±22.6%Aug 26 — IV 112% · EM ±22.5%Aug 27 — IV 98% · EM ±19.2%Aug 28 — IV 94% · EM ±18.0%Aug 31 — IV 102% · EM ±18.1%Sep 01 — IV 107% · EM ±18.4%Sep 02 — IV 105% · EM ±17.5%Sep 03 — IV 109% · EM ±17.6%Sep 04 — IV 109% · EM ±17.0%Sep 07 — IV 123% · EM ±17.0%Sep 08 — IV 128% · EM ±17.0%Sep 09 — IV 112% · EM ±14.0%Sep 10 — IV 116% · EM ±13.7%Sep 11 — IV 111% · EM ±12.3%Sep 14 — IV 126% · EM ±10.5%Sep 15 — IV 136% · EM ±9.9%Sep 16 — IV 136% · EM ±8.0%Sep 17 — IV 161% · EM ±6.7%Sep 21 — IV 102% · EM ±21.4%Sep 22 — IV 107% · EM ±21.8%Sep 23 — IV 110% · EM ±22.0%Sep 24 — IV 108% · EM ±21.1%Sep 25 — IV 106% · EM ±20.2%Sep 28 — IV 113% · EM ±20.0%Sep 29 — IV 116% · EM ±20.0%Sep 30 — IV 118% · EM ±19.7%Oct 01 — IV 110% · EM ±17.8%Oct 02 — IV 113% · EM ±17.6%Oct 06 — IV 120% · EM ±15.8%Oct 07 — IV 128% · EM ±16.0%Oct 08 — IV 181% · EM ±21.3%

Sector peers

DNTH
Dianthus Therapeutics, Inc.
$4.7B $76.78-1.7%
GMAB
Genmab A/S
$4.7B $43.79+10.7%
ERAS
Erasca, Inc.
$5.1B $14.39-0.7%
COGT
Cogent Biosciences, Inc.
$5.2B $31.21-0.7%
PTCT
PTC Therapeutics, Inc.
$5.3B $60.59-3.2%
INDV
Indivior Pharmaceuticals, Inc.
$4.3B $34.47-0.9%

MANE earnings FAQ

What is MANE's expected move for earnings?

Options currently price a move of about ±21.3%, or $29.61 per share either way from $138.78.

How does MANE stock usually react to earnings?

Across the last 1 reports the average next-day move was ±3.9%, up 0 times and down 1 times.

What is MANE's implied volatility?

MANE's at-the-money implied volatility is about 181% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in